Effect of Asian ginseng, Siberian ginseng, and Indian ayurvedic medicine Ashwagandha on serum digoxin measurement by Digoxin III, a new digoxin immunoassay.

Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center at Houston, Houston, Texas 77030, USA.
Journal of Clinical Laboratory Analysis (Impact Factor: 1.14). 01/2008; 22(4):295-301. DOI: 10.1002/jcla.20252
Source: PubMed

ABSTRACT Asian ginseng, Siberian ginseng, and Indian Ayurvedic medicine Ashwagandha demonstrated modest interference with serum digoxin measurements by the fluorescent polarization immunoassay (FPIA). Recently, Abbott Laboratories marketed a new digoxin immunoassay, Digoxin III for application on the AxSYM analyzer. We studied potential interference of these herbal supplements on serum digoxin measurement by Digoxin III assay in vitro and compared our results with the values obtained by Tina-quant assay. Aliquots of drug-free serum pool were supplemented with various amounts of Asian ginseng, Siberian ginseng, or Ashwagandha approximating expected concentrations after recommended doses and overdoses of these herbal supplements in serum. Then digoxin concentrations were measured by the Digoxin III and Tina-quant (Roche Diagnostics) assay. We also supplemented aliquots of a digoxin pool prepared from patients receiving digoxin with various amounts of these herbal supplements and then measured digoxin concentrations again using both digoxin immunoassays. We observed modest apparent digoxin concentrations when aliquots of drug-free serum pool were supplemented with all three herbal supplements using Digoxin III assay (apparent digoxin in the range of 0.31-0.57 ng/ml), but no apparent digoxin concentration (except with the highest concentration of Ashwagandha supplement for both brands) was observed using the Tina-quant assay. When aliquots of digoxin pool were further supplemented with these herbal supplements, digoxin concentrations were falsely elevated when measured by the new Digoxin III assay. For example, we observed 48.2% (1.63 ng/ml digoxin) increase in digoxin concentration when an aliquot of Digoxin pool 1 (1.10 ng/ml digoxin) was supplemented with 50 microl of Asian ginseng extract (Brand 2). Measuring free digoxin does not eliminate the modest interferences of these herbal supplements in serum digoxin measurement by the Digoxin III assay.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Asian, Siberian, and American ginseng are known to interfere with serum digoxin measurements using fluorescence polarization technology, Digoxin II and Digoxin III assays (Abbott Laboratories, Green oaks, IL) as well as other digoxin assays. Abbott Laboratories more recently launched two new digoxin assays: iDigoxin, a chemiluminescent microparticle immunoassay for application on the ARCHITECT i1000SR and i2000SR immunoassay analyzers, and cDigoxin, a particle-enhanced turbidimetric inhibition immunoassay for application on the ARCHITECT c4000, c8000, and c1600 clinical chemistry analyzers; and we studied potential interferences of ginsengs with these two assays in vitro. When aliquots of drug-free serum pool treated with activated charcoal were supplemented with extracts of various ginsengs, no significant apparent digoxin values were observed. In addition, when aliquots of the digoxin pool prepared from patients taking digoxin were further supplemented with these ginseng extracts and the digoxin values were re-measured, we observed no statistically significant difference in observed digoxin values compared to the original digoxin value of the pool. These results further establish that relatively new digoxin assays for application on the ARCHITECT analyzers that employ specific monoclonal antibodies against digoxin are free from interferences from Asian, Siberian, and American ginseng.
    Journal of Clinical Laboratory Analysis 03/2014; 29(1). DOI:10.1002/jcla.21714 · 1.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Globally, herbal medicines represent a $60 billion industry, and they account for approximately 20% of the overall drug market. Herbs (or herbals) that improve the taste of foods as flavor enhancement spices can generally be used safely by the CKD patient population. However, many herbals are sold as dietary supplements for medicinal use, and these are regulated as foods not drugs, thus allowing herbal supplements to be sold without premarket evaluation or approval by the Food and Drug Administration. In the absence of required testing, many herbal supplements are manufactured inconsistently with wide variations in composition. It is essential for the nephrology practitioner to assess CKD patients regarding their use of these products to understand their risks and benefits and to educate patients and families. This article will discuss some of the more commonly used products and their potential positive and adverse effects on CKD patients.
    Advances in Chronic Kidney Disease 07/2014; 21(4):377–384. DOI:10.1053/j.ackd.2014.05.001 · 1.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Herbal medicines supported by evidence of safety and efficacy in the treatment of anxiety, insomnia, fatigue, cognitive enhancement, mental focus, and sexual function are useful as monotherapies, multiherb combinations, and as adjuncts to prescription psychotropics. Relevant mechanisms of action and clinical guidelines for herbs in common use can assist clinicians who want to enhance treatment outcomes by integrating phytomedicinals into their treatment regimens. Research is needed to strengthen the evidence base and to expand the range of disorders that can be treated with herbal extracts. Studies of herbal genomic effects may lead to more targeted and effective treatments.
    The Psychiatric clinics of North America 03/2013; 36(1):37-47. DOI:10.1016/j.psc.2012.12.004 · 1.87 Impact Factor